Interestingly, all the four representative sublines obtained from in vivo tumor treatment with SAR405838 have the same sensitivity to the drug in the cell growth assay (Fig 5A), regardless of whether they retain p53 wild-type or a single heterozygous C176F p53 mutation or whether they are obtained with either one round or multiple rounds of the drug treatment in mice. The gene discussed is TP53; the disease is neoplasm.